Table 1 Design and outcomes of the studies included in the meta-analysis
Num | Author/ Year | Design | Intervention assignments | Participants | Outcomes | ||||
|---|---|---|---|---|---|---|---|---|---|
Baricitinib | Control | Sample size, n | Mean age, years(B/C) | Male:Female, (B/C) | Time of medication | ||||
1 | Bronte/2020 | PS, MC | 4mg bid for 2 days, followed by 4mg qd | conventional therapy | 76 | 68/77.5 | 7:13/31:25 | 7 days | All cause deaths; Incidence of ARDS; Duration of hospitalization |
2 | Kalil/2021 | RCTs,MC | 4-mg qd | Placebo | 1033 | 55/55.8 | 319:196/333:185 | 14 days or until hospital discharge | 14-day mortality, 28-day mortality Median time to recovery |
3 | Marconi/2021 | RCTs,MC | 4-mg qd | Placebo | 1525 | 57.8/57.5 | 490:274/473:288 | 14 days | 28-day mortality; Median time to recovery; Duration of hospitalisation |
4* | Ely/2022 | RCTs,MC | 4-mg qd | Placebo | 101 | 58.4/58.8 | 25:26/ 30:20 | 14 days | 28-day mortality;Treatment-emergent infection; DVT; PE; MACEs |
5* | Trøseid/2023 | RCTs,MC | 4-mg qd | Placebo | 275 | 59/60 | 112:27/99:37 | 14 days | 28-day mortality; 60-day mortality; Infections and infestations; DVT; PE; MACEs |